TRANSFUSION MEDICINE PROTOCOLS

Tetanus Immunoglobulin VF (For Intramuscular Use)

This document should be read in conjunction with the Disclaimer

DESCRIPTION	**Tetanus Immunoglobulin-VF (for intramuscular use)**
SPECIFICATIONS	Each ampoule contains 160 mg/mL plasma proteins and 22.5 mg/mL glycine. At least 98% of the proteins being immunoglobulins (mainly IgG), with a tetanus antitoxin activity of 100IU/mL. Manufactured from pooled human plasma. This product is for intramuscular use.Tetanus Immunoglobulin-VF IM Product Information
VIAL SIZE	250 IU vial
INDICATIONS	Passive protection of individuals who have sustained a tetanus-prone wound and who have either not been actively immunised against tetanus or whose immunisation history is doubtful. Refer to The Australian Immunization Handbook for more information. The WNHS Infection Control Manual is available for reference
CONTRAINDICATIONS AND PRECAUTIONS	Isolated immunoglobulin A (IgA) deficiency, unless they have been tested and shown not to have circulating anti-IgA antibodies. Severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections. Refer to the Tetanus Immunoglobulin-VF IM Product Detail for more information
CONSUMER INFORMATION	Tetanus Immunoglobulin IM Consumer Medicine Information
CONSENT	Manufactured from pooled human plasma. Refer to Transfusion Medicine Protocol WNHS Blood Product Prescription, Informed Consent. And Refusal

DOSE	Minimum routine prophylactic dose in adults and children is 250 IU. Refer to The Australian Immunization Handbook, Table 4.19.1: Guide to tetanus prophylaxis in wound management. Consult Consultant Microbiologist or Haematologist for advice.
ORDERING	Contact Transfusion Medicine Unit (TMU) and provide details of clinical history.
ADMINISTRATION	• Two staff to perform checks as per the Clinical Practice Manual, WNHS Pharmacy Medication Checking and Administration processes. Check Issue label and patient ID. Check right patient, right product, right dose – prescription matches product supplied. If not identical, contact TMU and prescribing doctor. • The product must be used immediately after opening. Any unused solution must be discarded. • Allow product to reach room temperature before administration. • Do not use the product if it appears turbid or cloudy. • Slow intramuscular (IM) injection. • **Tetanus Immunoglobulin-VF IM (for intramuscular use) MUST NOT be administered intravenously.**
OBSERVATIONS	Undertake observations as for all blood products. Vital signs (temperature, pulse, respiration, blood pressure) must be recorded on the observation chart in the medical record. Observe for signs of adverse reaction - see Tetanus Immunoglobulin-VF IM Product Information
ADVERSE REACTIONS	Local tenderness, erythema and stiffness may occur at the injection site and may persist for several hours. For more information see Tetanus Immunoglobulin-VF IM Product Information. Any adverse reaction should be reported to the Clinical Microbiologist/ Haematologist and TMU. Refer to WNHS Management of Transfusion Reactions and Adverse Events,
DOCUMENTATION	A record should be kept in the patient's history of the following: • The date and time of infusion • Patients observations and condition during the infusion • Amount given • The batch number and expiry date of each bottle used (place a sticker with the batch number on the Transfusion Medicine Record sheet MR735). This information is

	important should the patient have a reaction to the infusion or if there is a need to trace recipients of certain batch numbers at a later date.
For further information, refer to product insert Return product to TMU immediately if no longer required. Product should be used for intended patient (issue label) only.	

References

- Australian Government Department of Health, The Australian Immunisation Handbook, 10th Edition, 2013
- CSL Website and Product Information http://www.csl.com.au/products
- Tetanus Immunoglobulin-VF IM Product Detail
- CSL Global Tetanus Immunoglobulin-VF IM
- Australian Red Cross Blood Service – Blood products and transfusion practice for health professionals. http://www.transfusion.com.au/blood_products/fractionated_plasma/immunoglobulins
- The Australian Blood Service (ARCBS) Blood Component Information http://www.transfusion.com.au/sites/default/files/BCI%202009.pdf
- Flippin' Blood BloodSafe SA / ARCBS Second Edition June 2012 http://resources.transfusion.com.au/cdm/ref/collection/p16691coll1/id/20
- National Safety and Quality Health Service Standards, October 2012. Standard 7: Blood and Blood Products

Related WNHS policies, procedures and guidelines

- WNHS Blood Product Prescription, Consent and Refusal
- WNHS Management of Transfusion Reactions and Adverse Events
- WNHS Pharmacy Medication Checking and Administration
- Neonatology Clinical Care Guidelines
- Obstetrics and Gynaecology Clinical Guidelines

File path:	WNHS.HAEM.TetanusImmunoglobulinVFIntramuscular

Keywords:	Blood Transfusion, Blood products, plasma derived blood products. Blood bank, transfusion medicine unit, blood bank scientist, Tetanus immunoglobulin intramuscular, intramuscular tetanus immunoglobulin, tetanus immunoglobulin intramuscular administration		
Document owner:	Chair of KEMH Hospital Transfusion Committee		
Author / Reviewer:	Consultant Haematologist, Scientist in Charge Transfusion Medicine, KEMH Transfusion Coordinator		
Date first issued:	01 01 2005		
Last reviewed:	01 12 2015	Next review date:	01 02 2020
Endorsed by:	KEMH Hospital Transfusion Committee	Date:	01 02 2017
Standards Applicable:	NSQHS Standards: 1 Governance, 5 Patient ID/Procedure Matching, 7 Blood Products		
Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from the WNHS website.			